(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
16 June 2022 (16.06.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/125826 A1

(51) International Patent Classification:
A61K 31/47 (2006.01) *A61K 31/404* (2006.01)
A61K 31/395 (2006.01) *A61P 11/00* (2006.01)

(21) International Application Number:
PCT/US2021/062687

(22) International Filing Date:
09 December 2021 (09.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/123,928 10 December 2020 (10.12.2020) US
63/124,575 11 December 2020 (11.12.2020) US
63/150,434 17 February 2021 (17.02.2021) US

(71) Applicant: **VERTEX PHARMACEUTICALS INCORPORATED** [US/US]; 50 Northern Avenue, Boston, Massachusetts 02210 (US).

(72) Inventors: **BOREK, Bartlomiej**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **CHEN, Weichao George**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **GUNAWAN, Rudy**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **HASELTINE, Eric**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **NAIR, Nitin**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **PANORCHAN, Porntula**; 50 Northern Avenue, Boston, Massachusetts 02210 (US). **SOSNAY, Patrick**; 50 Northern Avenue, Boston, Massachusetts 02210 (US).


(74) Agent: **MCDONELL, Leslie A.** et al.; Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, 901 New York Avenue, NW, Washington, District of Columbia 20001 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: METHODS OF TREATMENT FOR CYSTIC FIBROSIS



I

(57) Abstract: This application describes methods of treating cystic fibrosis or a CFTR mediated disease comprising administering Compound I or a pharmaceutically acceptable salt thereof. The application also describes pharmaceutical compositions comprising Compound I or a pharmaceutically acceptable salt thereof and optionally comprising one or more additional CFTR modulating agents.

WO 2022/125826 A1